Prevention of sexually transmitted infections in the era of antibiotic resistance
https://doi.org/10.21518/ms2025-435
Abstract
The descriptive review presents modern strategies for the prevention of sexually transmitted infections (STIs) in the context of increasing resistance of microorganisms to antibiotics at present. WHO materials, recommendations of leading professional communities, and clinical studies were used for the analysis. The main measures to combat STIs in the world and in Russia include organizational activities, raising public awareness, and increasing the use of personal protective equipment. The article presents established facts about the resistance of STI pathogens to antimicrobial drugs and measures to limit the spread of resistant microorganisms. In the context of restrictions associated with antibiotic resistance for treatment, the issue of STI prevention is especially acute. Approaches to primary and secondary prevention of STIs are described. The main attention is paid to post-exposure prophylaxis (doxycycline, antimicrobial agents), information is provided on their effectiveness and limitations. The rationale for the use of Miramistin® for post-exposure prophylaxis is given. Conducted studies of the antimicrobial activity and clinical effectiveness of Miramistin® convince us that this drug has high potential in the fight against STIs, both bacterial and viral.
Keywords
Supporting agencies: the article was prepared with the support of INFAMED LLC. This did not influence the author’s opinion in any way
About the Author
G. B. Dikke
Аcademy of Medical Education named F.I. Inozemtsev
Russian Federation
Russian Federation
Galina B. Dikke - Dr. Sci. (Med.), Professor of the Department of Obstetrics and Gynecology with a Course of Reproductive Medicine.
22, Letter M, Moscow Ave., St Petersburg, 190013
References
1. Rakhmatulina MR, Melekhina LE, Novoselova EYu. A retrospective analysis of the increase in syphilis incidencein the Russian Federation in 2009–2023 and trends in dynamic development of epidemiological processes. Vestnik Dermatologii i Venerologii. 2025;101(1):7–27. (In Russ.) https://doi.org/10.25208/vdv16851.
2. Rakhmatulina MR, Novoselova EYu, Melekhina LE. Analysis of the epidemiological situation and dynamics of the incidence of sexually transmitted infections in the Russian Federation over a ten-year period (2012–2022). Vestnik Dermatologii i Venerologii. 2024;100(1):8–23. (In Russ.) https://doi.org/10.25208/vdv16741.
3. Ivanova MA, Varavikova EA. Incidence of sexually transmitted infections and prevention of their spread in the Russian Federation and abroad. Current Problems of Health Care and Medical Statistics. 2022;(3):459–477. (In Russ.) https://doi.org/10.24412/2312-2935-2022-3-459-477.
4. Dikke GB. New initiatives and recommendations of the World Health Organization for the prevention and treatment of sexually transmitted infections. Farmateka. 2017;(3):6–11. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/34498.
5. Rodríguez-García A, Botello-Hermosa A, Borrallo-Riego Á, Guerra-Martín MD. Effectiveness of Comprehensive Sexuality Education to Reduce Risk Sexual Behaviours Among Adolescents: A Systematic Review. Sexes. 2025;6(1):6. https://doi.org/10.3390/sexes6010006.
6. Kim EJ, Park B, Kim SK, Park MJ, Lee JY, Jo AR et al. A Meta-Analysis of the Effects of Comprehensive Sexuality Education Programs on Children and Adolescents. Healthcare. 2023;11(18):2511. https://doi.org/10.3390/healthcare11182511
7. Pallotta VI, Sichkar TV. Psychological and pedagogical aspect of adolescent sex education. World of Science. Pedagogy and Psychology. 2022;10(2):54PDMN222. (In Russ.) Available at: https://mir-nauki.com/PDF/54PDMN222.pdf.
8. Zakharova EK. Representation of Institutional Attitudes Towards Adolescent Sexual Education in Russian Media. The Journal of Social Policy Studies/ Zhurnal Issledovaniy Sotsial’noy Politiki. 2023;21(2):293–310. (In Russ.) https://doi.org/10.17323/727-0634-2023-21-2-293-310.
9. Stover J, Teng Y. The impact of condom use on the HIV epidemic. Gates Open Res. 2022;5:91. https://doi.org/10.12688/gatesopenres.13278.2.
10. Paz-Bailey G, Koumans EH, Sternberg M, Pierce A, Papp J, Unger ER et al. The Effect of Correct and Consistent Condom Use on Chlamydial and Gonococcal Infection Among Urban Adolescents. Arch Pediatr Adolesc Med. 2005;159(6):536–532. https://doi.org/10.1001/archpedi.159.6.536.
11. Dikke GB, Erofeeva LV. Contraception Russia today: use and awareness (a population-based study). Akusherstvo i Ginekologiya (Russian Federation). 2016;(2):108–113. (In Russ.) https://doi.org/10.18565/aig.2016.2.108-113.
12. Henderson JT, Senger CA, Henninger M, Bean SI, Redmond N, O’Connor EA. Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;324(7):682–699. https://doi.org/10.1001/jama.2020.10371.
13. Hufstetler K, Llata E, Miele K, Quilter LAS. Clinical Updates in Sexually Transmitted Infections, 2024. J Womens Health. 2024;33(6):827–837. https://doi.org/10.1089/jwh.2024.0367.
14. Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments. Arch Pathol Lab Med. 2020;144(11):1344–1351. https://doi.org/10.5858/arpa.2020-0118-RA.
15. Whitlock GG, Gibbons DC, Longford N, Harvey MJ, McOwan A, Adams EJ. Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. Int J STD AIDS. 2018;29(5):474–482. https://doi.org/10.1177/0956462417736431.
16. Ogale YP, Grabowski MK, Nabakka P, Ddaaki W, Nakubulwa R, Nakyanjo N et al. The Acceptability of Self-Collected Samples for STI Testing: A Qualitative Study Among Adults in Rakai, Uganda. MedRxiv. 2023:2023.02.17.23286055. https://doi.org/10.1101/2023.02.17.23286055.
17. Dikke GB. Modern strategies for increasing the efficiency of organized screening programs for cervical cancer. Issues of Practical Colposcopy. Genital Infections. 2022;(3):8–16. (In Russ.) https://doi.org/10.46393/27826392_2022_3_8.
18. Turner KME, Looker KJ, Syred J, Zienkiewicz A, Baraitser P. Online testing for sexually transmitted infections: A whole systems approach to predicting value. PLoS ONE. 2019;14(2):e0212420. https://doi.org/10.1371/journal.pone.0212420.
19. Eckman MH, Reed JL, Trent M, Goyal MK. Cost-effectiveness of Sexually Transmitted Infection Screening for Adolescents and Young Adults in the Pediatric Emergency Department. JAMA Pediatr. 2021;175(1):81–89. https://doi.org/10.1001/jamapediatrics.2020.3571.
20. Cantor A, Dana T, Griffin JC, Nelson HD, Weeks C, Winthrop KL, Chou R. Screening for Chlamydial and Gonococcal Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;326(10):957–966. https://doi.org/10.1001/jama.2021.10577.
21. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–532. https://doi.org/10.1016/S0140-6736(13)62218-7.
22. Dusheiko G. Towards the elimination and eradication of hepatitis B. J Virus Erad. 2015;1(1):4–12. https://doi.org/10.1016/S2055-6640(20)31151-1.
23. Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, Markowitz LE. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction – National Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis. 2017;216(5):594–603. https://doi.org/10.1093/infdis/jix244.
24. Bebneva TN. Human papillomavirus. Global strategy to eliminate cervical cancer. Obstetrics and Gynecology Today. 2025;(3):10–11. (In Russ.) Available at: https://abvpress.ru/upload/iblock/035/035d11e07d4711272c08d69eee84dc6d.pdf.
25. Chang JY, Balch C, Oh HS. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. Viruses. 2024;16(9):1476. https://doi.org/10.3390/v16091476.
26. Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr. 2013;63(Suppl. 1):S12–S25. https://doi.org/10.1097/QAI.0b013e31829202a2.
27. Белова ЕГ, Бессараб ТП, Волова ЛА, Гаджикулиева ММ, Гейне МД, Гусев ДА и др. ВИЧ-инфекция у взрослых: клинические рекомендации. М.; 2024. 143 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/79_2.
28. Кубанов АА, Соколовский ЕВ, Красносельских ТВ, Катунин ГЛ, Плахова КИ, Мавлютова ГИ и др. Сифилис: клинические рекомендации. М.; 2024. 85 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/197_2.
29. Кубанов АА, Серов ВН, Абудуев НК, Аполихина ИА, Богданова ЕВ, Васильев ММ и др. Гонококковая инфекция: клинические рекомендации. М.; 2024. 36 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/218_2.
30. Кубанов АА, Серов ВН, Рахматулина МР, Аполихина ИА, Гомберг МА, Горбунова ЕА и др. Хламидийная инфекция: клинические рекомендации. М.; 2024. 42 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/194_2.
31. Chakraborty A. Preand Post-Exposure Prophylaxis in Sexually Transmitted Diseases: An Uncharted Territory. Indian J Dermatol. 2024;69(6):471–474. https://doi.org/10.4103/ijd.ijd_828_22.
32. Liao Y, Wen Z, Shi M, Zou H, Sun C. Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination. Viruses. 2025;17(6):756. https://doi.org/10.3390/v17060756.
33. Sokoll PR, Migliavaca CB, Döring S, Traub U, Stark K, Sardeli AV. Efficacy of postexposure prophylaxis with doxycycline (Doxy-PEP) in reducing sexually transmitted infections: a systematic review and meta-analysis. Sex Transm Infect. 2025;101(1):59–67. https://doi.org/10.1136/sextrans-2024-056208.
34. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023;388(14):1296–1306. https://doi.org/10.1056/NEJMoa2211934.
35. Boschiero MN, Sansone NMS, Matos LR, Marson FAL. Efficacy of Doxycycline as Preexposure and/or Postexposure Prophylaxis to Prevent Sexually Transmitted Diseases: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2025;52(2):65–72. https://doi.org/10.1097/OLQ.0000000000002082.
36. Allan-Blitz LT, Mayer KH. Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infections: The Current Landscape and Future Directions. Curr HIV/AIDS Rep. 2024;22(1):1. https://doi.org/10.1007/s11904-024-00709-w.
37. Imerlishvili E, Lake J, Todorovic S, Gonzalez C, Boos EM, Hart-Malloy R. Doxycycline post-exposure prophylaxis for preventing bacterial sexually transmitted infections (STIs): Are clinical providers supportive? Int J STD AIDS. 2025;36(4):297–303. https://doi.org/10.1177/09564624241309433.
38. Liang P, Zhao P, Huang S, Wang C. Willingness to accept Doxycycline postexposure prophylaxis for bacterial stis prevention among men who have sex with men in Southern China: a cross-sectional analysis. BMC Infect Dis. 2025;25(1):911. https://doi.org/10.1186/s12879-025-11290-x.
39. Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K et al. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1–8. https://doi.org/10.15585/mmwr.rr7302a1.
40. Mirzaeei S, Zangeneh M, Veisi F, Parsa S, Hematti M. Chlorhexidine, clotrimazole, metronidazole and combination therapy in the treatment of vaginal infections. J Med Life. 2021;14(2):250–256. https://doi.org/10.25122/jml-2019-0160.
41. Eckel F, Farr A, Deinsberger J, Kernmayer-Farr K, Foessleitner P. Dequalinium Chloride for the Treatment of Vulvovaginal Infections: A Systematic Review and Meta-Analysis. J Low Genit Tract Dis. 2024;28(1):76–83. https://doi.org/10.1097/LGT.0000000000000790.
42. La Verde M, Torella M, Iavarone I, Molitierno R, Cerillo A, Casillo M et al. Vaginal Cleansing and Post-Cesarean Infectious Morbidity? Updated Systematic Review and Meta-Analysis of Randomized Trials. Biomedicines. 2025;13(6):1505. https://doi.org/10.3390/biomedicines13061505.
43. Mendez F, Castro A. Prevention of sexual transmission of AIDS / STD by a spermicide containing benzalkonium chloride. Arch AIDS Res. 1990;4(1-2):115–135. Available at: https://pubmed.ncbi.nlm.nih.gov/12283019/.
44. Osmanov A, Farooq Z, Richardson MD, Denning DW. The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. FEMS Microbiol Rev. 2020;44(4):399–417. https://doi.org/10.1093/femsre/fuaa012.
45. Rishchuk SV, Gusev SN, Dushenkova TA. Use of the drug Miramistin® in reproductively significant pathology. Terra Medica. 2012;(1):18–23. (In Russ.) Available at: http://www.terramedica.spb.ru/all/public/pdf/terra/1-67-2012-f9.pdf.
46. Krivoshein YuS, Skuratovich AA, Rudko AP. Use of surfactants for the prevention of experimental syphilis. Vestnik Dermatologii i Venerologii. 1983;(11):29–32. (In Russ.)
47. Kenyon CR, Schwartz IS. Effects of Sexual Network Connectivity and Antimicrobial Drug Use on Antimicrobial Resistance in Neisseria gonorrhoeae. Emerg Infect Dis. 2018;24(7):1195–1203. https://doi.org/10.3201/eid2407.172104.
48. Robinson LR, McDevitt CJ, Regan MR, Quail SL, Swartz M, Wadsworth CB. Revisiting the potential impact of doxycycline post-exposure prophylaxis on the selection of doxycycline resistance in Neisseria commensals. Sci Rep. 2025;15:12400. https://doi.org/10.1038/s41598-025-96244-8.
49. Williams E, Zhang B, Chow EPF, Chea S, Phillips TR, Maddaford K et al. Inhibitory Activity of Antibacterial Mouthwashes and Antiseptic Substances against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2022;66(6):e0004222. https://doi.org/10.1128/aac.00042-22.
50. Abdrahmanov RM, Faizullina EV, Abdrahmanov AR, Haliullin RR. To the issue of local treatment in combination therapy of chronic urethritis, associated with sexually transmitted infections. Urologiia. 2015;(6):40–46. (In Russ.) Available at: https://urologyjournal.ru/articles/K-voprosu-o-mestnom-lechenii-v-kompleksnoi-terapii-hronicheskih-uretritovassociirovannyh-s-infekciyami-peredavaemymi-polovym-putem.html.
51. Kirichenko IM. Use of the drug Miramistin® in infectious pathology in gynecology. Poliklinika. 2013;(6):98–100. (In Russ.) Available at: https://www.elibrary.ru/tpwcct.
52. Pasechnikov SP, Nikitin OD. Complex treatment of urogenital chlamydia using Miramistin solution. Clinical Achievements. 2008;(3):69–71. (In Russ.) Available at: http://health-medix.com/articles/liki_ukr/2008-04-15/69-71.pdf.
53. Kirichenko IM. Combined therapy of chronic and indolent forms of urogenital infections using Miramistin®. Medical Alphabet. 2014;(24):18–20. (In Russ.) Available at: https://www.pharmaclon.ru/upload/iblock/b61/b616eabde7b26ba11ec6559e5efe9bc5.pdf.
54. Moreva ZhG, Garasko EV. Peculiarities of antimicrobic preparations influence on trichomonas in vitro. Bulletin of the Ivanovo Medical Academy. 2006;11(3-4):17–24. (In Russ.) Available at: https://vestnik-ivgma.ru/issues/5/publications/93.
55. Kirichenko IM, Barinsky IF, Alimbarova LM. Study of antiviral properties of miramistin in vitro against herpes simplex virus types 1 and 2. Effective Pharmacotherapy. Dermatovenereology and Dermatocosmetology. 2012;(2):28–57. (In Russ.) Available at: https://www.elibrary.ru/skfvzf.
56. Zarochentseva NV, Belaya YM, Samsygina GA, Shcherbakova MYu, Vyzhlova EN. Recurring anogenital condyloma patient management. Clinical VIFERON® administration case. Feron Bulletin. 2017;(4):26–29. (In Russ.) Available at: https://viferon.su/2015/wp-content/uploads/2017/12/VestnikFerona_04_2017.pdf.
57. Vasilyeva TV, Raskidaylo AS, Arutcheva AA. Antibacterial activity and clinical efficacy of the new antiseptic drug miramistin. Antibiotiki i Khimioterapiya. 1993;38(8-9):61–63. (In Russ.)
58. Agafonova MN, Kazakova RR, Lubina AP, Zeldi MI, Nikitina EV, Balakin KV, Shtyrlin YG. Antibacterial activity profile of miramistin in in vitro and in vivo models. Microb Pathog. 2020;142:104072. https://doi.org/10.1016/j.micpath.2020.104072.
59. Молочков ВА, Арзуманян ВГ, Кириченко ИМ. Изучение противогрибкового действия препаратов мирамистина in vitro и эффективность их применения в дерматологии. М.: ММА им. И.М.Сеченова, НИИ вакцин и сывороток им. И.И. Мечникова; 2003.
60. Dunaevsky AM, Kirichenko IM. Clinical rationale for the use of Miramistin in the treatment of infectious and inflammatory diseases of the respiratory system. Poliklinika. 2013;(5):6–12. (In Russ.) Available at: https://www.poliklin.ru/imagearticle/201305(3)/6-12.pdf.
61. Arzumanyan VG. Minimum inhibitory concentrations of some antifungal drugs for clinically significant basidomycete yeasts. Antibiotiki i Khimioterapiya. 2002;47(2):7–10. (In Russ.)
62. Krivorutchenko YuL, Kirsanova MA, Postnikova ON. Sensitivity to miramistin, amphotericin B and tauroside Sx1 of fungi isolated from patients in Crimea. Biomedical and Biosocial Anthropology. 2010;(15):144–149. (In Russ.)
63. Osmanov A, Wise A, Denning DW. In vitro and in vivo efficacy of miramistin against drug-resistant fungi. J Med Microbiol. 2019;68(7):1047–1052. https://doi.org/10.1099/jmm.0.001007.
64. Danilova TA, Danilina GA, Adzhieva AA, Minko AG, Nikolaeva TN, Zhukhovitskii VG, Pronin AV. Effects of Miramistin and Phosprenil on Microbial Biofilms. Bull Exp Biol Med. 2017;163(4):439–442. https://doi.org/10.1007/s10517-017-3823-x.
65. Andreeva VO, Levkovich MA. Efficacy of Topical Miramistin® in Treatment of Non-Specific Vulvovaginitis in Sickly Girls. Effective pharmacotherapy. Obstetrics and Gynecology. 2016;(4):14–20. (In Russ.) Available at: https://umedp.ru/upload/iblock/fa3/miramistin.pdf.
66. Mironova AV. Opportunities of Using Miramistin® in Practice of Pediatric and Adolescent Gynecologist (Literature Review). Effective pharmacotherapy. Obstetrics and Gynecology. 2016;(14):42–46. (In Russ.) Available at: https://umedp.ru/upload/iblock/7dd/miramistin.pdf.
67. Dovletkhanova ER, Abakarova PR. Current trends in treatment of vulvovaginitis. Effective Pharmacotherapy. Obstetrics and Gynecology. 2014;(35):12–16. (In Russ.) Available at: https://umedp.ru/upload/iblock/5e5/5e5ad0a77b07574755981c599cf334cf.pdf.
68. Dikke GB. New dosage form of Miramistin for the treatment of vulvovaginal infections. Women’s Clinic. 2023;(1):51–60. (In Russ.) Available at: https://elibrary.ru/wfiguz.
69. Podzolkova NM, Zefirova TP, Sozaeva LG, Sadykova DA. Vaginal infections in pregnant women: diagnostics, new paradigms of therapy. Gynecology. 2025;27(1):4–11. (In Russ.) https://doi.org/10.26442/20795696.2025.1.203164.
70. Obiero J, Ogongo P, Mwethera PG, Wiysonge CS. Topical microbicides for preventing sexually transmitted infections. Cochrane Database Syst Rev. 2021;(3):CD007961. https://doi.org/10.1002/14651858.CD007961.pub3.
71. Zyryanov SK. Clinical and pharmacological analysis of the application of antiseptic drugs in practical medicine. Pharmacology & Pharmacotherapy. 2022;(1):10–24. (In Russ.) Available at: https://doi.org/10.46393/27132129_2022_1_10.
Review
For citations:
Dikke GB. Prevention of sexually transmitted infections in the era of antibiotic resistance. Meditsinskiy sovet = Medical Council. 2025;(17):62-72. (In Russ.) https://doi.org/10.21518/ms2025-435
Views:
9
Email this article 